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Abstract
Background: Emerging evidence suggests that vascular disease confers vulnerability to a late-onset of depressive illness
and the impairment of specific cognitive functions, most notably in the domains of memory storage and retrieval. Lower
limb athero-thrombosis and abdominal aortic aneurysm (AAA) have both been previously associated with neuropsychiatric
symptoms possibly due to associated intracerebral vascular disease or systemic inflammation, hence suggesting that these
illnesses may be regarded as models to investigate the vascular genesis of neuropsychiatric symptoms. The aim of this study
was to compare neuropsychiatric symptoms such as depression, anxiety and a variety of cognitive domains in patients who
had symptoms of peripheral athero-thrombosis (intermittent claudication) and those who had an asymptomatic abdominal
aortic aneurysm AAA.
Methodology/Principal Findings: In a cross-sectional study, 26 participants with either intermittent claudication or AAA
were assessed using a detailed neuropsychiatric assessment battery for various cognitive domains and depression and
anxiety symptoms (Hamilton Depression and Anxiety Scales). Student t test and linear regression analyses were applied to
compare neuropsychiatric symptoms between patient groups. AAA participants showed greater levels of cognitive
impairment in the domains of immediate and delayed memory as compared to patients who had intermittent claudication.
Cognitive dysfunction was best predicted by increasing aortic diameter. CRP was positively related to AAA diameter, but not
to cognitive function. AAA and aortic diameter in particular were associated with cognitive dysfunction in this study.
Conclusions/Significance: AAA patients are at a higher risk for cognitive impairment than intermittent claudication
patients. Validation of this finding is required in a larger study, but if confirmed could suggest that systemic factors peculiar
to AAA may impact on cognitive function.
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Introduction
New evidence is emerging suggesting that vascular disease
confers vulnerability to a late-onset of depressive illness and the
impairment of specific cognitive functions, most notably in the
domains of memory storage and retrieval [1,2]. The relationship
between vascular disease and cognitive functions is pathophysio-
logically and clinically complex and the underlying biological
mechanisms are not well understood [3].
The term ‘‘Vascular Depression’’ has been used to describe the
broad nature of late-life depression resulting from a multitude of
potential vascular mechanisms. Consistent with the Vascular
Depression Hypothesis, patients with a later onset of depression
have greater neuropsychological and neuroradiological abnormal-
ities, increased disability, medical morbidity and mortality [4,5,6].
Whilst the vascular depression topic has received much attention
in the literature, the mechanisms through which this relationship is
mediated are however unclear. For instance, depression can be
understood in terms of the consequence of, or as an independent
risk factor for vascular disease, which has been overwhelmingly
evident in cases of coronary heart disease (CHD). Patients with a
history of ischemic heart disease were more likely to suffer from
depression than control patients of similar age and social class [7].
Likewise, depression has been found to be a significant risk factor
for cardiac mortality in both men and women [8]. In addition,
depression has also been more frequently observed in patients after
having suffered a stroke [9].
Traditionally, psychological and psychiatric conditions such as
stress and depression have been associated with poor immune
system function and an increased susceptibility towards infectious
disease and illness [10]. One of the oldest and most consistent
biological disturbances in depression is the dysregulation of the
hypothalamic-pituitary-adrenal (HPA) axis [11,12]. HPA func-
tion is vital to the regulation of glucocorticoid release and
impairment of this function has been shown to induce
hypercholesterolemia, hypertriglyceridemia, hypertension and
impairment of vascular endothelial cells [13]. Some researchers
[13] argue that high levels of cortisol are also significantly
associated with the severity and progression of CHD. Other
research has also highlighted the presence of immunological
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events occurring in depressed patients [14] suggesting that
immune activation may be causal in the onset of depression
[15]. The administration of inflammatory cytokine interleukin-1
(IL-1), induces a series of symptoms referred to as ‘sickness
behaviour’, which is closely associated with the symptomology of
depressive illness [16]. Interestingly, other inflammatory markers
such as C-reactive protein (CRP) and interleukin-6 (IL-6) which
are typically associated with CHD have been discovered in the
blood samples of depressed patients [17].
The same vascular mechanisms which are associated with
vascular depression may also increase vulnerability towards
cognitive decline and dementia [2,18]. Hypertension, atrial
fibrillation and low levels of high-density lipoprotein are
significantly associated with low cognitive performance and
subcortical features including Parkinsonism, gait disturbance and
impaired executive function [19]. These findings are consistent
with more recent evidence suggesting that vascular pathology is
closely associated with cognitive impairment [2,20,21,22]. Evi-
dence from immunological studies suggests that pro-inflammatory
cytokines (IL-1b, IL-6 and TNF-a) are implicated in the
development and progression of cognitive dysfunction [23,24].
Research on the association between peripheral vascular diseases
and mood and cognitive performance is an area which requires
more attention in order to explore the mechanisms of this
relationship further.
The current investigation aims to explore the relationship
between abdominal aortic aneurysms (AAA) and the symptoms of
depression and cognitive functioning. Both local and systemic
inflammation has been identified in patients with AAA, with
increased circulating levels of a range of cytokines previously
identified, such as resistin and osteopontin (OPN) [25,26]. Such
circulating cytokines could impact upon cognitive and emotional
centres in the brain. We are aware of no published studies in
which neuropsychiatric symptoms have been assessed in patients
with AAA except around the time of surgery [27]. Research in this
area is particularly significant given that the number of patients
with AAA appears to be increasing [28]. In addition, the study
may also be helpful to improve the understanding of the vascular
genesis of neuropsychiatric symptoms.
It is hypothesised that patients with infrarenal AAA have an
increased risk towards the symptoms of depression and cognitive
impairment in comparison to patients with occlusive atheroscle-
rosis (without AAAs). We chose these two groups of patients since
the mechanisms underlying the pathogenesis of abdominal aortic
aneurysm (AAA) and occlusive atherosclerosis appears to have a
number of distinctions [29]. An example is the negative association
of diabetes with AAA but its positive association with occlusive
athero-thrombosis [30]. There is also evidence that certain
circulating cytokines and biomarkers may be distinct to aortic
aneurysm [31]. Based on these differences between aortic
aneurysm and athero-thrombosis it was hypothesised that the
association with neuropsychiatric symptoms and these diseases
may also be distinct. In order to examine this hypothesis we
assessed a range of neuropsychiatric symptoms such as depression,
anxiety and a variety of cognitive domains in a group of subjects
with asymptomatic AAAs and a separate collection of patients who
had symptoms of lower limb athero-thrombosis, namely intermit-
tent claudication, but did not have AAAs.
Methods
Study Population
Participants in the current study were recruited from around
the local Townsville area that had undergone, or were currently
receiving treatment for a blood vessel disease in the Vascular
Clinic at The Townsville Hospital. Prior to invitation, par-
ticipants were screened in order to assess research suitability.
Only participants with either symptoms of intermittent
claudication or an AAA were invited to participate. Ethics
approval was provided by the local ethics committees of the
Townsville Hospital and James Cook University. Participants
gave written informed consent to participate in the study prior
to commencing any study procedures. Participants were either
contacted at home or were directly approached during
consultation hours at the Vascular Clinic. Collection and
analysis of blood serum was processed by a commercial
pathology laboratory (Sullivan Nicolaides Pathology). Pathology
tests included full blood count, fasting lipids, electrolytes and
urea. Physician based medical history confirmed that all patients
were free of mental retardation or dementia history or other
psychiatric disorders such as schizophrenia. Participation in the
research was entirely voluntary and no incentives were offered
for participation.
Assessment of cognitive functioning
The cognitive status of participants was assessed using the
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
[32]. The RBANS is a brief individually administered tool which
measures five domains of cognitive function including attention,
language, visuospatial/constructional abilities, and immediate and
delayed memory. The RBANS was developed primarily as a
neurological assessment tool for dementia in the elderly. However,
success for screening neurocognitive status in younger patients has
also been highlighted [33]. Patient fatigue is a drawback of many
existing forms of neurological testing which are often lengthy in
design, and in some instances may exceed 6 hours [34]. Low
administration times allow the RBANS to be administered in as
little as 20 minutes, making it ideal for use with elderly patients
[33].
Normative data is based on a standardised U.S. sample of 540
adults aged 20–89 years. Factors such as age, sex, race/ethnicity,
education level and geographic region were evenly weighed in
accordance with 1995 Census data. Reliability coefficients for each
index were calculated using spilt-half reliability and Spearman-
Brown correction. Reliability coefficients calculated for each
subtest and age group ranged from .77 to .95 [33]. Content
validity of the RBANS is deemed adequate and comparable to
similar clinical tests including the WAIS-III, Boston Naming Test and
verbal fluency tests. Inter-correlation scores between indexes
remained at a moderate range of .20–.40, suggesting that each
RBANS index is measuring different and distinct cognitive
constructs [33].
Assessment of Depression and Anxiety
Depressive and anxiety symptoms were assessed using the
Hamilton Depression and Anxiety Scales. The Hamilton scales is a semi-
structured interview consisting of 17 items which assess depressed
mood, suicide, work and loss of interest, retardation, agitation,
gastro-intestinal symptoms, general somatic symptoms, hypochon-
driasis, insight and weight loss [35]. The Hamilton Scales was one
of the first psychometric tools for the assessment of depression
[36], and currently remains one of the most widely used clinical
measures for depression [37]. Internal consistency and test-retest
reliability coefficients were .91 and .96 respectively, indicating
suitability for use in clinical applications [37]. Measures of validity
were sufficient across scales with correlations between the
Hamilton Depressive Inventory, the Beck Depression Scale and
the Beck Hopelessness Scale were .93 and .79 respectively [37].
Neuropsychiatry in AAA
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The Hamilton Depressive Inventory also performed well in
discriminating between groups of depressed and non-depressed
patients. A significant difference (p,.0001) was found between
depression, anxiety and control groups [37].
Assessment of AAA, intermittent claudication and other
risk factors
Patients recruited to the study had either an AAA or
intermittent claudication. Intermittent claudication was diagnosed
by a consultant vascular physician based on an appropriate history
along with clinical signs of lower limb ischemia and computed
tomography angiography (CTA) evidence of occlusive or stenotic
peripheral artery disease. AAA was defined as maximal infra-renal
abdominal aortic diameter $30 mm from axial slices of the CTA.
Patients with AAA included in the current study did not have
symptoms of intermittent claudication or clinical evidence of
impaired lower limb blood supply. Patients with intermittent
claudication included in the current study had an AAA excluded
by CTA imaging (aortic diameter ,30 mm). Hypertension and
diabetes were defined by previous history or treatment for these
conditions. Cigarette smoking classification was based on smoking
history (defined as ever or never smokers). CHD was defined by a
history of myocardial infarction, angina or coronary revascular-
isation. Body mass index (BMI) was calculated as weight(kg)/
height(m)2. Specific blood tests for this analysis included C-reactive
protein (CRP), Haemoglobin (HB g/l), Triglycerides (TAG) and
Low Density Lipoprotein (LDL).
Statistical Analysis
Demographic and clinical data were compared between AAA
and intermittent claudication groups using Chi-square test for
categorical data and two sample t-test for continuous data
(Table 1). We employed univariate analyses for mean comparison
across three groups (age, education, marital status) and student t-
test for comparison of means of two groups (patient groups,
gender, smoking status) as shown in Table 2. In addition, we used
student t-test for mean comparisons of individual and summary
cognitive test scores from the RBANS across both vascular patient
groups (AAA vs IC) (Table 3). Linear regression analysis was used
to assess the within-group effects adjusted for age and education
(Table 4). Gender was excluded as a covariate on a methodological
basis as only 1 female was assessed in the AAA group. All statistical
analyses were carried out using SPSS 16.0 for Windows (SPSS,
Chicago, IL, USA).
Results
A total of 26 patients were assessed for depression, anxiety and
cognitive functioning. The sample included 20 male (M=70.3
years, SD=6.3 years) and 6 female (M=66.1 years, SD=1.27
years) participants of Caucasian descent. Measure of education
was total years of school completed, the sample ranged from 8–
11 years (M=9.1years, SD= .82 years). The AAA group
consisted of 10 males and 1 female whilst the intermittent
claudication group had 10 males and 5 females. Sociodemo-
graphic and clinical characteristics such as diabetes, hyperten-
sion, smoking, CHD, BMI and CRP showed no significant
differences between the AAA and intermittent claudication
groups (Table 1). Approximately 19% of all participants were
classified as depressed (HAM-D score . 8). Interestingly,
symptoms of depression and/or anxiety were not significantly
associated with age, gender, education, marital status or vascular
group, whereas the total cognitive test score showed a significant
difference between vascular groups indicating a poorer overall
cognitive performance of the AAA group. Summary levels of
depression, anxiety and cognitive functioning stratified by age,
gender, education, marital status and vascular group are
presented in Table 2.
Table 3 presents between-group comparisons of both single
cognitive test scores and summary scores. The RBANS total score
was compared between the AAA and intermittent claudication
patient groups and revealed a significant difference between both
groups (p=0.028) with AAA patients performing worse than
intermittent claudication patients. AAA group participants
generally scored worse on most individual and summary cognitive
scores as compared to intermittent claudication participants.
Significant differences were noted on tasks involving short and
Table 1. Basic socio-demographic and clinical characteristics
of patients with AAA or Intermittent Claudication.
N
AAA
N=11
IC
N=15 p-value *
Ages, N (%)
Mean, SD
43–64
26
9
72.4, 5.7
2 (18.2)
67.2, 9.0
7 (26.9)
0.11
0.31
65–74 8 4 (36.4) 4 (26.7)
75–80 9 5 (45.5) 4 (26.7)
Gender, N (%)
Male 20 10 (90.1) 10 (66.7) 0.15
Female 6 1 (9.09) 5 (33.3)
Education, N (%)
Mean, SD
8 Years
26
6
9.0, 0.7
2 (18.2)
9.1, 0.9
7 (46.7)
0.89
0.31
9 Years 12 5 (45.5) 5 (33.3)
10+ Years 8 4 (36.4) 3 (20.0)
Marital Status, N (%)
Married 17 7 (63.6) 10 (66.7) 0.58
Divorced 4 2 (18.2) 2 (13.3)
Single# 5 2 (18.2) 3 (20.0)
Smoking, N (%) 0.748
Never smoked 8 4 (36.4) 4 (26.7)
Ever smoked 18 7 (63.6) 11 (73.3)
Diabetes, N (%)
(2 missing)
0.39
Yes 11 4 (36.4) 7 (53.9)
No 13 7 (63.6) 6 (46.1)
Hypertension, N (%)
(2 missing)
0.85
Yes 17 8 (72.7) 9 (69.2)
No 7 3 (27.3) 4 (30.8)
CHD, N (%) (5 missing) 0.28
Yes 10 6 (60.0) 4 (36.4)
No 11 4 (40.0) 7 (63.6)
BMI (kg/m2), mean (SD) 29.7 (4.4) 29.8 (4.1) 0.97
CRP, mean (SD) 4.2 (2.8) 3.2 (2.5) 0.11
SD denotes standard deviation; AAA denotes abdominal aortic aneurysm; IC
denotes intermittent claudication; CHD denotes coronary heart disease; BMI
denotes body mass index; CRP denotes C-Reactive Protein;# includes ‘widowed’
participants;
* p-value of Chi-square test for categorical data and two sample t-test for
continuous data.
doi:10.1371/journal.pone.0022632.t001
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long-term memory (Table 3). Participants in the AAA group also
displayed difficulties in domains of language and attention as
indicated by the mean scores; however, these differences were not
significant.
Linear regression analyses displayed in Table 4 investigated the
potential effect of biological variables on the memory domains
(immediate and delayed) and the total score which as shown above
had demonstrated significant differences between AAA and
intermittent claudication patients. As a main result aortic diameter
increase was associated with reduced immediate (effect size
r=0.51; adjusted R2= 0.24) and delayed memory retention (effect
size r=0.47; adjusted R2= 0.21) and overall cognitive functioning
(effect size r=0.43; adjusted R2= 0.16) (see Table 4 for details). In
contrast, blood serum levels of C-reactive protein, haemoglobin,
triglycerides and low density lipoprotein showed no significant
association with immediate or delayed memory function, either in
the whole sample or in the subgroups of patients with AAA or
intermittent claudication. Additional adjustment for CHD,
hypertension, smoking and diabetes did not change this associa-
tion.
In additional analyses we observed in the whole sample, that
CRP serum levels were significantly associated with aortic
diameter after adjustment for age and education (t = 2.6;
p = 0.021) indicating a relationship between aortic development
and systemic inflammation, which may indicate an indirect
relationship between CRP and memory function in our study;
however no direct evidence was found for this assumption.
Discussion
In this cross-sectional study of vascular patients, we examined if
neuropsychiatric and neurocognitive symptoms were associated
with AAA presence. We found that overall cognitive function and
specifically short-term and delayed memory were associated with
AAA. Furthermore aortic diameter was associated with worse
cognitive scores in the memory domains. In contrast, no
association between depressive or anxiety symptoms and AAA
was observed.
The findings of this small study suggest worse cognition function
in patients with AAA compared to those with occlusive peripheral
artery disease. There are numerous possible explanations for these
findings. AAA has been associated with distinct circulating
concentrations of biomarkers, including pro-inflammatory cyto-
kines, proteolytic enzymes and thrombus products [31]. Recently
for example we demonstrated that patients with AAA have higher
plasma concentrations of D-dimer compared to those with
intermittent claudication [38]. Such circulating products could
cross the blood brain barrier and influence cognitive performance.
Indeed an association between circulating thrombus products and
cognition has been reported in other cohorts [39,40]. Pro-
inflammatory cytokines are also upregulated in patients with
AAA, such as resistin, osteoprotegerin and osteopontin [26,41,42].
Such circulating cytokines could also alter central nervous system
(CNS) immunological function which is believed to influence
memory and learning [43]. It is acknowledged that cytokines
Table 2. Neurocognitive and Psychiatric Symptoms across Vascular Sample.
N
RBANS
Total Score
(Mean, SD)
Hamilton Depression
Score (HAM-D -17)
(Mean, SD)
Hamilton Anxiety Score
(HAM-A -14)
(Mean, SD)
Ages
43–64 9 99.4 (18.1) 5.0 (3.5) 5.1 (2.8)
65–74 8 96.7 (15.5) 4.7 (6.8) 5.0 (5.3)
75–80 9 87.4 (19.5) 3.4 (4.3) 3.2 (3.4)
Gender
Male 20 96.8 (17.3) 4.1 (4.7) 4.1 (3.7)
Female 6 86.6 (19.5) 5.1 (5.5) 5.3 (4.5)
Education
8 Years 6 90.8 (1.1) 2.3 (1.8) 3.6 (1.9)
9 Years 12 94.4 (2.1) 6.5 (5.9) 5.6 (4.6)
10+ Years 8 97.2 (2.1) 2.7 (3.3) 3.1 (3.5)
Smoking
Never smoked 8 106.2 (19.9) 4.4 (5.7) 5.6 (6.7)
Ever smoked 18 91.7 (16.8) 4.4 (1.0) 4.1 (3.1)
Marital Status
Married 17 95.9 (19.3) 4.8 (5.4) 4.8 (4.5)
Divorced 4 97.0 (9.8) 2.7 (3.4) 2.2 (1.8)
Single# 5 87.4 (19.3) 4.2 (3.9) 4.6 (1.8)
Patient Groups
IC 15 100.8 (18.2) 4.2 (4.1) 4.3 (3.1)
AAA 11 85.7 (14.0) * 4.6 (5.8) 4.5 (4.8)
AAA denotes abdominal aortic aneurysm; IC denotes intermittent claudication; RBANS denotes Repeatable Battery for the Assessment of Neuropsychological Status; #
includes ‘widowed’ participants:
* p-value derived from univariate analysis for mean comparison of variables with three groups (age, education, marital status) and student t-test for comparison of
means of variables with two groups (patient groups, gender): p-value = 0.031.
doi:10.1371/journal.pone.0022632.t002
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produced in the periphery can circulate through the blood stream
to other areas of the body including the CNS [44]. Communi-
cation with brain neurons can occur via direct penetration of the
blood brain barrier, or through activation of the vagus nerve
within the abdominal and thoracic cavity, which communicates
with neuronal populations in the brainstem [45]. In the current
study we measured circulating concentrations of a general marker
of systemic inflammation CRP. We found a significant association
between CRP serum levels and aortic diameter, as has been
previously reported [46], however in this study CRP was not
associated with cognitive function. It is possible that specific
cytokines, such as osteopontin which are known to modulate
chronic inflammation through actions on T cells and macrophag-
es, may be more relevant to cognitive impairment than a general
marker of inflammation. However, these biomarkers apart from
CRP were not measured in our study, suggesting further studies
are required in this area.
Early perspectives on systemic inflammation suggested that the
CNS was not susceptible to inflammation or immune activation,
and was considered to be mostly unaffected by systemic
inflammatory and immune response [47]. A more modern opinion
now suggests that the brain controls and regulates many aspects of
immune response and activation. Recent studies of stroke, multiple
sclerosis, Alzheimer’s and depressive illness suggest there is a
strong interconnection between the immune, endocrine, central
and autonomic nervous systems [47] [48]. Immunological studies
have focused primarily on the action and reaction of cytokines in
response to inflammatory stimuli. Studies suggest that cytokines
are highly influential and may act either synergistically or
antagonistically towards each other [48]. However, by virtue of
effect, cytokines may influence or contribute to symptoms of
behavioural pathologies. Extensive research [23,24,49,50] has
found that pro-inflammatory cytokines including IL-1b, IL-6 and
TNF-a are strongly associated with cognitive decline and motor
retardation particularly amongst elderly populations. This follows
more recent evidence citing the existence of a ‘Cytokine Model of
Cognitive Function’. The model proposes that pro-inflammatory
cytokines play an intimate role in the molecular and cellular
mechanisms sub-serving learning, memory and cognition [43].
The model provides a basis from which to explore complex
neuropsychiatric conditions such as cognitive decline, dementia
and depression resulting from cytokine activation.
It is possible that cytokines, such as resistin and OPN, which are
upregulated in AAA, may also exert their effects on pro-
inflammatory cytokines (IL-1b, IL-6, IL-8 and TNF-a) either
directly in the CNS, or through a process of peripheral
inflammation. It is not yet clear if resistin and OPN are capable
of crossing the blood brain barrier; however evidence suggests that
it may indeed be possible given the small physical profile of the
molecules [51,52].
Another possible reason for the association between cognition
and AAA identified in the current study could be associated
intracerebral vascular disease. Intracerebral vascular disease is one
of the commonest causes of dementia. It is possible that the
Table 3. RBANS Single Cognitive Test and Summary Scores
across Vascular Groups.
AAA group
N=11
IC group
N=15 p-value{
Age, mean (SD) 72.3 (5.7) 67.2 (9.0) n.s.
Education in years, mean (SD) 9.0 (.70) 9.1 (.91) n.s.
Single test scores, mean (SD)
List Learning 17.6 (3.9) 23.7 (6.2) .027
Story Memory 9.0 (4.0) 14.8 (5.0) .010
Figure Copy 18.5 (1.2) 18.4 (2.7) n.s.
Line Orientation 15.9 (2.8) 15.0 (5.1) n.s.
Picture Naming 9.8 (.40) 10.0 (0.0) n.s.
Semantic Fluency 22.5 (6.3) 29.0 (6.1) .022
Digit Span 10.8 (2.5) 9.6 (2.2) n.s.
Coding 35.9 (12.3) 43.2 (13.0) n.s.
List Recall 2.4 (2.9) 4.0 (2.3) n.s.
List Recognition 16.6 (2.8) 18.2 (2.0) n.s.
Story Recall 4.1 (3.5) 7.6 (3.1) .042
Figure Recall 10.9 (4.7) 14.5 (4.0) n.s.
Summary scores, mean (SD)
Immediate Memory 67.0 (11.2) 88.3 (21.2) .009
Visuospatial/Constructional 99.9 (15.1) 103.1 (21.9) n.s.
Language 107.9 (13.9) 118.2 (12.3) n.s.
Attention 40.8 (36.1) 45.8 (33.9) n.s.
Delayed Memory 77.5 (21.7) 95.0 (16.9) .044
Total Score 85.7 (14.0) 100.8 (18.2) .028
AAA denotes abdominal aortic aneurysm; IC denotes intermittent claudication;
RBANS denotes Repeatable Battery for the Assessment of Neuropsychological
Status; SD denotes standard deviation;
{ p-values derived from student t test for mean comparison across two groups
(AAA vs IC); n.s. denotes not significant.
doi:10.1371/journal.pone.0022632.t003
Table 4. Impact of Serum Biomarkers on Memory Domains of Cognitive Function in Overall Sample.
Immediate Memory{ Delayed Memory{ Total Score{
beta 95% CI beta 95%CI beta 95%CI
Aortic dia. 20.52 212.04 – 20.05* 20.49 212.6 – 21.2* 20.44 210.9 – 22.9*
CRP 20.05 22.9 – 2.3 0.09 22.2 – 3.3 0.17 21.5 – 3.2
HB g/l 0.07 20.57 – 0.79 0.17 20.4 – 0.91 0.07 20.5 – 0.7
TAG 20.25 20.16 – 4.5 20.14 214.5 – 7.70 20.25 214.4 – 4.1
LDL 20.24 212.36 – 3.44 20.38 214.7 – 0.70 20.3 211.4 – 2.1
{Linear regression adjusted for age and education; beta = standardized beta-coefficient; CI = confidence interval;
*significant at p,0.05;
CRP: C-reactive protein; HB g/l: Haemoglobin g/l; Aortic dia: aortic diameter; TAG: Triglycerides; LDL: low density lipoprotein.
doi:10.1371/journal.pone.0022632.t004
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patients with AAA we studied could have more severe vascular
pathology, including intracerebral disease, than those with
intermittent claudication. We did not image the brains of patients
in this study making further assessment of this impossible.
Limitations
The findings from this study should be interpreted in light of
methodological limitations particularly in relation to the size and
representativeness of the sample. The predictive power of the
findings must also be received with some caution. Statistical error
must be considered with any research, however, studies with small
samples are particularly vulnerable to sampling errors leaving
uncertainty about the negative results on depression in this study.
Another limitation which should be considered is the role of
gender. Gender amongst age and education is generally
acknowledged as a mediating factor in cognitive function [53].
Whilst gender effects were still present in the current findings,
females were underrepresented particularly in the AAA group.
Future research should focus on achieving more equal gender
samples in order to thoroughly examine the differences. Similarly,
ethnicity and socio-economic status was limited by patient
availability to Caucasians living in lower socio-economic status
areas of Townsville. The ability to generalise these results to more
diverse cultural backgrounds and other socio-economic groups is
reduced and should also be considered for future research.
Although in this study, smoking, diabetes, hypertension and BMI
showed no significant differences across both vascular groups
(AAA vs IC), future studies should consider these and additional
factors such as alcohol consumption and severity of atherosclerotic
disease as potential confounders.
Further study in this area would be to first replicate the current
findings using a larger sample of participants with a greater
emphasis on gender and socio-economic status. Whilst the current
study has identified observable cognitive differences between
genders, the sample remains too small to make any broad
generalisations to the general population. Another aspect which
was not examined in this study is the relationship between specific
cytokines and cognitive function in patients with AAA. In
particular, systemic inflammatory markers resistin and osteopontin
have been implicated in the pathogenesis of AAA, however, their
role in cognitive functioning is currently unknown. Further
research needs to closely examine this potential relationship.
In conclusion, this study suggests that AAA and aortic diameter
are associated with cognitive performance. Systemic inflammatory
and vascular changes related to AAA could account for this
association, however further studies are required to examine this.
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